期刊
CLINICAL SCIENCE
卷 118, 期 11-12, 页码 717-725出版社
PORTLAND PRESS LTD
DOI: 10.1042/CS20090537
关键词
anterior gradient protein 2 (AGR2); biomarker; CA125; ELISA; ovarian cancer
资金
- Healthlinx Ltd
- National Health and Medical Research Council of Australia
- U.K. Higher Education Innovation Fund through the Genetic Innovation Network
- UK North West Development Agency
- Medical Research Council [G0801447] Funding Source: researchfish
- MRC [G0801447] Funding Source: UKRI
Ovarian cancer is often asymptomatic and is diagnosed at an advanced stage with poor survival rates, thus there is an urgent need to develop biomarkers for earlier detection of ovarian cancer. In the present study, we demonstrate for the first time that the previously reported metastasis-inducing protein AGR2 (anterior gradient protein 2) can be detected in the blood of ovarian cancer patients. Using a newly developed ELISA, we show significantly increased concentrations of AGR2 protein in plasma from cancer patients relative to normal controls. Plasma AGR2 concentrations were highest in stages II and III ovarian cancer patients and were similarly elevated in patients with both serous and non-serous tumours. The identification of elevated plasma concentrations of AGR2 may provide a useful biomarker to aid in the discrimination of normal and ovarian cancer patients particularly when used in combination with CA125.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据